title: Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection.
abstract: Cathelicidin antimicrobial peptides are effectors of innate immune defense in mammals. Humans and mice have only one cathelicidin gene, whereas domesticated mammals such as the pig, cow, and horse have multiple cathelicidin genes. We hypothesized that the evolution of multiple cathelicidin genes provides these animals with enhanced resistance to infection. To test this, we investigated the effects of the addition of cathelicidins by combining synthetic cathelicidin peptides in vitro, by producing human keratinocytes that overexpress cathelicidins in culture, or by producing transgenic mice that constitutively overexpress cathelicidins in vivo. The porcine cathelicidin peptide PR-39 acted additively with human cathelicidin LL-37 to kill group A Streptococcus (GAS). Lentiviral delivery of PR-39 enhanced killing of GAS by human keratinocytes. Finally, transgenic mice expressing PR-39 under the influence of a K14 promoter showed increased resistance to GAS skin infection (50% smaller necrotic ulcers and 60% fewer surviving bacteria). Similarly constructed transgenic mice designed to overexpress their native cathelicidin did not show increased resistance. These findings demonstrate that targeted gene transfer of a xenobiotic cathelicidin confers resistance against infection and suggests the benefit of duplication and divergence in the evolution of antimicrobial peptides.
authors.affiliation: Division of Dermatology, University of California at San Diego, San Diego, CA 92161, USA.
authors.forename: Phillip H A
authors.initials: PH
authors.lastname: Lee
authors.forename: Takaaki
authors.initials: T
authors.lastname: Ohtake
authors.forename: Mohamed
authors.initials: M
authors.lastname: Zaiou
authors.forename: Masamoto
authors.initials: M
authors.lastname: Murakami
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Rudisill
authors.forename: Kenneth H
authors.initials: KH
authors.lastname: Lin
authors.forename: Richard L
authors.initials: RL
authors.lastname: Gallo
mesh_terms: D000818:Animals; D023181:Antimicrobial Cationic Peptides / Q000502:physiology*; D006801:Humans; D015603:Keratinocytes / Q000378:metabolism / Q000382:microbiology; D051379:Mice; D008822:Mice, Transgenic; D017192:Skin Diseases, Bacterial / Q000517:prevention & control*; D013290:Streptococcal Infections / Q000517:prevention & control; D013297:Streptococcus pyogenes; D013552:Swine; D054804:Cathelicidins
chemical_list: D023181:Antimicrobial Cationic Peptides; C072212:PR 39; D054804:Cathelicidins
references.citation: Nat Med. 2000 Jan;6(1):49-55
references.pmid: 10613823
references.citation: Semin Cutan Med Surg. 2000 Mar;19(1):19-61
references.pmid: 10834604
references.citation: Vet Res. 2000 May-Jun;31(3):277-96
references.pmid: 10863946
references.citation: Int Microbiol. 1998 Dec;1(4):279-84
references.pmid: 10943375
references.citation: Oncology (Williston Park). 2000 Aug;14(8 Suppl 6):9-16
references.pmid: 10989819
references.citation: Blood. 2001 Jan 1;97(1):297-304
references.pmid: 11133774
references.citation: J Invest Dermatol. 2001 Jul;117(1):91-7
references.pmid: 11442754
references.citation: Clin Microbiol Infect. 2001;7 Suppl 2:1-7
references.pmid: 11525214
references.citation: J Cell Physiol. 2001 Nov;189(2):133-43
references.pmid: 11598898
references.citation: Nature. 2001 Nov 22;414(6862):454-7
references.pmid: 11719807
references.citation: Curr Opin Hematol. 2002 Jan;9(1):18-22
references.pmid: 11753073
references.citation: Eur J Cancer Care (Engl). 2001 Mar;10(1):56-62
references.pmid: 11827268
references.citation: Drug Resist Updat. 2001 Aug;4(4):225-32
references.pmid: 11991677
references.citation: Arch Pharm Res. 2002 Apr;25(2):111-36
references.pmid: 12009024
references.citation: Curr Opin Biotechnol. 2002 Jun;13(3):267-74
references.pmid: 12180104
references.citation: J Mol Med (Berl). 2002 Sep;80(9):549-61
references.pmid: 12226737
references.citation: N Engl J Med. 2002 Oct 10;347(15):1151-60
references.pmid: 12374875
references.citation: Infection. 2002 Oct;30(5):257-61
references.pmid: 12382082
references.citation: J Dent Res. 2002 Dec;81(12):845-50
references.pmid: 12454100
references.citation: J Allergy Clin Immunol. 2002 Dec;110(6):823-31
references.pmid: 12464945
references.citation: Nature. 2003 Apr 3;422(6931):522-6
references.pmid: 12660734
references.citation: J Invest Dermatol. 2003 May;120(5):810-6
references.pmid: 12713586
references.citation: Int J Infect Dis. 2003 Mar;7(1):46-52
references.pmid: 12718810
references.citation: J Pharm Pharm Sci. 2003 Jan-Apr;6(1):67-83
references.pmid: 12753730
references.citation: J Hosp Infect. 2003 Oct;55(2):156-7
references.pmid: 14529646
references.citation: Proc Natl Acad Sci U S A. 1980 Dec;77(12):7380-4
references.pmid: 6261253
references.citation: Anal Biochem. 1987 Apr;162(1):156-9
references.pmid: 2440339
references.citation: Proc Natl Acad Sci U S A. 1989 Mar;86(5):1563-7
references.pmid: 2466292
references.citation: FEMS Microbiol Lett. 1991 Aug 1;66(2):219-24
references.pmid: 1936949
references.citation: Eur J Biochem. 1991 Dec 18;202(3):849-54
references.pmid: 1765098
references.citation: J Biol Chem. 1993 Mar 15;268(8):6058-63
references.pmid: 8449963
references.citation: Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11035-9
references.pmid: 7972004
references.citation: J Leukoc Biol. 1997 May;61(5):624-9
references.pmid: 9129212
references.citation: Infect Immun. 1998 Apr;66(4):1671-9
references.pmid: 9529097
references.citation: Chem Biol. 1998 Apr;5(4):197-207
references.pmid: 9545431
references.citation: J Clin Invest. 1999 Apr;103(8):1113-7
references.pmid: 10207162
references.citation: Nature. 1999 Jun 10;399(6736):590-3
references.pmid: 10376600
references.citation: Science. 1999 Oct 1;286(5437):113-7
references.pmid: 10506557